Core Viewpoint - Rhythm Pharmaceuticals has received a positive opinion from the European Medicines Agency's CHMP to expand the marketing authorization for IMCIVREE® (setmelanotide) to treat obesity and control hunger in patients aged 4 and above with acquired hypothalamic obesity, with a final decision expected in Q2 2026 [1][2] Group 1: Company Overview - Rhythm Pharmaceuticals is a commercial-stage biopharmaceutical company focused on rare neuroendocrine diseases, with its lead product IMCIVREE® approved in the U.S. for treating acquired hypothalamic obesity and other genetic obesity syndromes [4][5] - The company is advancing a broad clinical development program for setmelanotide and other investigational MC4R agonists, as well as preclinical small molecules for congenital hyperinsulinism [4] Group 2: Acquired Hypothalamic Obesity - Acquired hypothalamic obesity is characterized by accelerated weight gain due to hypothalamic injury, leading to reduced energy expenditure and hyperphagia, with an estimated 10,000 patients in both the U.S. and EU affected by this condition [3] - The condition often follows the treatment of hypothalamic-pituitary tumors and is driven by impairment of the MC4R pathway, indicating a significant unmet medical need for effective treatments [3][2] Group 3: Regulatory Developments - The positive CHMP opinion follows recent FDA approval, reinforcing the quality of data supporting Rhythm's filings for acquired hypothalamic obesity and highlighting the company's global drug development strategy [2] - The European Commission will review the CHMP opinion, with a final decision anticipated in the second quarter of 2026, which could expand the market for IMCIVREE in the EU [1][2]

Core Insights - PANTHERx Rare Pharmacy has been selected by Rhythm Pharmaceuticals as the exclusive U.S. pharmacy distribution partner for the expanded indication of IMCIVREE (setmelanotide) for treating acquired hypothalamic obesity in adults and children aged 4 and older [1][2] Company Overview - PANTHERx Rare specializes in patient access and support services for personalized rare disease care, focusing on making complex therapies more accessible through individualized case management and comprehensive support [1][2] - Since its founding in 2011, PANTHERx has grown to become the largest independent rare pharmacy in the U.S., maintaining a balance between established resources and small-company responsiveness [2][3] Product and Indication Details - IMCIVREE is indicated for chronic weight management in patients aged 2 years and older with obesity due to specific genetic conditions, including Bardet-Biedl Syndrome and deficiencies in POMC, PCSK1, or LEPR [2] - Acquired hypothalamic obesity is characterized by accelerated weight gain due to hypothalamic injury, often resulting from tumors or other neurological conditions [4] Collaboration and Support - The partnership with Rhythm Pharmaceuticals aims to provide high-touch clinical support to patients navigating treatment for acquired hypothalamic obesity, which has historically had limited therapeutic options [2] - PANTHERx employs its proprietary RxARECARE model to enhance patient and caregiver support, ensuring a personalized approach to therapy management [1][2]

Core Viewpoint - Rhythm Pharmaceuticals has received FDA approval for an expanded indication of IMCIVREE (setmelanotide) to treat acquired hypothalamic obesity, marking it as the first and only FDA-approved therapy for this condition [7][9]. Company Overview - Rhythm Pharmaceuticals is a commercial-stage biopharmaceutical company focused on rare neuroendocrine diseases, with its lead product IMCIVREE designed to treat hyperphagia and severe obesity [16]. - The company estimates approximately 10,000 individuals in the U.S. are affected by acquired hypothalamic obesity [9][15]. Product Details - IMCIVREE is indicated for reducing excess body weight and maintaining long-term weight reduction in adults and pediatric patients aged 4 years and older with acquired hypothalamic obesity [17]. - The approval is based on the Phase 3 TRANSCEND trial, which demonstrated a statistically significant -18.4% placebo-adjusted reduction in body mass index (BMI) [6][10]. Clinical Trial Results - In the TRANSCEND trial, participants on setmelanotide achieved a -15.8% reduction in BMI compared to a +2.6% increase in the placebo group at 52 weeks [10]. - Setmelanotide was generally well tolerated, with common adverse events including skin hyperpigmentation, nausea, vomiting, and headache [10][27]. Market Implications - The approval of IMCIVREE addresses a critical unmet need for patients with acquired hypothalamic obesity, providing a targeted therapy that addresses the underlying biology of the disease [9][10]. - The company is committed to supporting patient access to IMCIVREE through programs like Rhythm InTune, which offers educational support and assistance with insurance navigation [12].

Core Insights - Rhythm Pharmaceuticals has received FDA approval for IMCIVREE® (setmelanotide) as the first and only therapy for acquired hypothalamic obesity, a rare condition leading to significant weight gain due to hypothalamic injury or dysfunction [2][4][10] - The approval is based on the results from the Phase 3 TRANSCEND trial, which demonstrated a statistically significant -18.4% placebo-adjusted reduction in body mass index (BMI) among participants [3][5][6] Company Overview - Rhythm Pharmaceuticals is a commercial-stage biopharmaceutical company focused on rare neuroendocrine diseases, with IMCIVREE as its lead asset [11] - The company estimates approximately 10,000 individuals in the U.S. are affected by acquired hypothalamic obesity, highlighting a significant unmet medical need [4][10] Product Details - IMCIVREE is indicated for adults and pediatric patients aged 4 years and older with acquired hypothalamic obesity, aiming to reduce excess body weight and maintain long-term weight reduction [3][12] - The therapy has also been approved for syndromic or monogenic obesity due to conditions such as Bardet-Biedl syndrome and POMC deficiency in patients aged 2 years and older [11][13] Clinical Trial Results - The Phase 3 TRANSCEND trial involved 142 patients, where those treated with setmelanotide achieved a -15.8% reduction in mean BMI compared to a +2.6% increase in the placebo group at 52 weeks [5][6] - Setmelanotide was generally well tolerated, with common adverse events including skin hyperpigmentation, nausea, vomiting, and headache [5][21] Support and Access - Rhythm Pharmaceuticals is committed to ensuring patient access to IMCIVREE, with a support program called Rhythm InTune that provides educational resources and assistance with insurance navigation [7] - The company will host a conference call to discuss the FDA approval and its implications for patients and healthcare providers [8]

Core Insights - Rhythm Pharmaceuticals presented four data presentations at ObesityWeek® 2025, showcasing the efficacy of setmelanotide in treating acquired hypothalamic obesity [1][2][5] Company Overview - Rhythm Pharmaceuticals is a commercial-stage biopharmaceutical company focused on rare neuroendocrine diseases, with its lead product, setmelanotide (IMCIVREE®), approved for treating obesity related to specific genetic conditions [6][9][10] Clinical Data Highlights - Setmelanotide demonstrated a mean placebo-adjusted BMI reduction of 27.1% in patients receiving concomitant GLP-1 therapy and a 19.0% reduction in patients treated with setmelanotide alone [8][7] - Significant improvements in cardiometabolic health were observed in patients treated with setmelanotide, including better blood pressure and lipid levels [3][7] - Patient-reported outcomes indicated meaningful changes in hunger, weight, energy levels, and physical activity among participants in the TRANSCEND trial [2][3] Research Presentations - Dr. Christian Roth presented findings on the robust efficacy of setmelanotide in reducing BMI compared to previous anti-obesity treatments [2] - A poster by Dr. Jennifer Miller highlighted significant improvements in cardiometabolic parameters associated with setmelanotide treatment [3] - Dr. Roohi Kharofa's research focused on hyperphagia and genetic variants in early-onset obesity, involving data from 212 participants [4]

Core Viewpoint - Rhythm Pharmaceuticals has announced an extension of the FDA review period for the supplemental New Drug Application (sNDA) for IMCIVREE® (setmelanotide) by three months, moving the PDUFA goal date from December 20, 2025, to March 20, 2026 [1][2] Company Overview - Rhythm Pharmaceuticals is a commercial-stage biopharmaceutical company focused on rare neuroendocrine diseases, with its lead product IMCIVREE® (setmelanotide) aimed at treating acquired hypothalamic obesity [1][6] - Setmelanotide is already approved by the FDA for reducing excess body weight in patients aged 2 years and older with specific genetic obesity syndromes [6][7] Regulatory Update - The FDA requested additional sensitivity analyses of clinical efficacy data from Rhythm's Phase 3 pivotal trial, which has been classified as a 'major amendment' allowing for an extended review period [2] - No new safety or manufacturing data was requested by the FDA, indicating that the focus remains on the efficacy data [2] Management Commentary - David Meeker, CEO of Rhythm, expressed confidence in the product profile of setmelanotide and the ongoing collaboration with the FDA to bring the treatment to patients who currently lack approved options [3] Conference Call Information - Rhythm Pharmaceuticals will hold a conference call and webcast to discuss the update at 8:00 a.m. ET, with registration recommended ten minutes prior to the start [4][5]

Core Insights - Rhythm Pharmaceuticals has entered into Product Listing Agreements for IMCIVREE in several Canadian provinces, allowing public reimbursement for eligible patients with Bardet-Biedl syndrome and obesity [1][2][3] - The approval of IMCIVREE by Health Canada in May 2023 and its inclusion in the National Strategy for Drugs for Rare Diseases is a significant advancement for patients [2][4] - The agreements highlight the recognition of the burden of obesity associated with Bardet-Biedl syndrome and the company's commitment to equitable access for all patients in Canada [3][4] Company Overview - Rhythm Pharmaceuticals is a biopharmaceutical company focused on rare neuroendocrine diseases, with its lead product IMCIVREE (setmelanotide) approved for weight management in patients with specific genetic conditions [4][5] - IMCIVREE is indicated for weight management in patients aged 6 years and older with obesity due to Bardet-Biedl syndrome and other genetic deficiencies [5][6] - The company is also advancing a clinical development program for additional rare diseases and investigational MC4R agonists [4][5] Product Information - IMCIVREE is an MC4R agonist that has received regulatory approvals in Canada, the U.S., and Europe for treating obesity related to Bardet-Biedl syndrome and other genetic conditions [4][6][8] - The product is administered via subcutaneous injection and is indicated for patients with genetically confirmed conditions [5][6] - The company emphasizes the importance of physician supervision for prescribing IMCIVREE in the EU and UK [8]

Core Viewpoint - Rhythm Pharmaceuticals, Inc. is set to report its third quarter 2025 financial results and provide a corporate update on November 4, 2025, at 8:00 a.m. ET [1] Company Overview - Rhythm Pharmaceuticals is a commercial-stage biopharmaceutical company focused on rare neuroendocrine diseases [3] - The company's lead product, IMCIVREE® (setmelanotide), is an MC4R agonist approved by the FDA for treating obesity related to specific genetic conditions [3][4] - Setmelanotide is indicated for patients aged 2 years and older with syndromic or monogenic obesity due to Bardet-Biedl syndrome (BBS) or deficiencies in POMC, PCSK1, or LEPR [4][5] Upcoming Events - Rhythm will host a live conference call and webcast for its financial results on November 4, 2025 [1] - The company will also participate in two fireside chats on November 12, 2025, at the Guggenheim Healthcare Innovation Conference and the Stifel Healthcare Conference [7] Product Indications - In the U.S., setmelanotide is indicated for long-term weight reduction in patients with specific genetic obesity conditions [4] - In the EU and UK, it is indicated for obesity treatment and hunger control associated with genetically confirmed BBS or related deficiencies [5] Limitations and Contraindications - Setmelanotide is not indicated for obesity due to benign variants of POMC, PCSK1, or LEPR [6][8] - Serious hypersensitivity reactions have been reported, contraindicating its use in patients with prior serious hypersensitivity to the drug [9] Warnings and Precautions - Patients may experience disturbances in sexual arousal, depression, and hypersensitivity reactions [10][11][12] - Skin hyperpigmentation and the development of new melanocytic nevi have been observed, necessitating regular skin examinations [13] Adverse Reactions - Common adverse reactions (≥20% incidence) include skin hyperpigmentation, injection site reactions, nausea, headache, and depression [15]

Core Viewpoint - Rhythm Pharmaceuticals, Inc. is set to report its second quarter 2025 financial results and provide a corporate update on August 5, 2025, highlighting its focus on rare neuroendocrine diseases and the development of its lead asset, setmelanotide [1][4]. Company Overview - Rhythm Pharmaceuticals is a commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with rare neuroendocrine diseases [4]. - The company's lead product, IMCIVREE® (setmelanotide), is an MC4R agonist approved by the FDA for reducing excess body weight and maintaining weight reduction in patients aged 2 years and older with specific genetic obesity conditions [4][5]. - Setmelanotide is also authorized by the European Commission and the UK's MHRA for similar indications in adults and children [4][6]. Upcoming Events - Rhythm Pharmaceuticals will host a live conference call and webcast on August 5, 2025, at 8:00 a.m. ET to discuss its financial results [1]. - Alastair Garfield, Chief Scientific Officer, and David Connolly, Head of Investor Relations, will participate in a fireside chat at the Canaccord Genuity 45th Annual Growth Conference on August 13, 2025, at 12:30 p.m. ET [2]. Product Indications - In the U.S., setmelanotide is indicated for patients with syndromic or monogenic obesity due to Bardet-Biedl syndrome (BBS) or deficiencies in POMC, PCSK1, or LEPR [5]. - In the EU and UK, it is indicated for obesity treatment and hunger control associated with genetically confirmed BBS or loss-of-function biallelic POMC, including PCSK1 and LEPR deficiencies [6]. Clinical Development - Rhythm is advancing a broad clinical development program for setmelanotide in other rare diseases and is also exploring investigational MC4R agonists, bivamelagon and RM-718, along with a preclinical suite of small molecules for congenital hyperinsulinism [4].

Core Insights - Rhythm Pharmaceuticals is set to disclose topline results from a Phase 2 trial evaluating bivamelagon for acquired hypothalamic obesity on July 9, 2025 [1][2] Company Overview - Rhythm Pharmaceuticals is a commercial-stage biopharmaceutical company focused on rare neuroendocrine diseases [4] - The company's lead asset, IMCIVREE® (setmelanotide), is approved for treating obesity related to specific genetic conditions [4][5] - Rhythm is advancing a clinical development program for setmelanotide and other investigational MC4R agonists, including bivamelagon and RM-718 [4] Bivamelagon Phase 2 Trial Details - The Phase 2 trial is a randomized, placebo-controlled, double-blind study involving 28 patients aged 12 and older [3] - Patients received daily oral doses of bivamelagon (200 mg, 400 mg, or 600 mg) or placebo for 14 weeks [3] - The primary endpoint is the change in body mass index after 14 weeks of treatment, with an option for patients to continue therapy for up to 52 weeks [3]